BPC-157 (Body Protection Compound)

BPC-157 is a pentadecapeptide derived from a gastric protein, studied for tissue repair, tendon healing, and gut-barrier effects. This hub covers mechanism, oral vs injection routes, dosing protocols, and the comparison with TB-500.

All BPC-157 articles (3)

The First Properly Controlled Human BPC-157 Trial Is Finally Enrolling
BPC-157

The First Properly Controlled Human BPC-157 Trial Is Finally Enrolling

For nearly three decades BPC-157 has been one of the most-discussed research peptides on the internet, built on a mountain of rodent data and almost no human trials. In February 2026, that gap started to close. Hudson Biotech began enrolling NCT07437547 — a 120-participant, randomised, double-blind, placebo-controlled Phase 2 trial in acute hamstring strain. Here is the design, what it will tell us, and what it won't.

Oct 13, 2026 Read more →

Frequently Asked Questions

Is BPC-157 effective taken orally?

Animal research suggests BPC-157 retains some biological activity when administered orally, particularly for GI endpoints (ulcer healing, colitis). Systemic bioavailability is poorly characterized in humans and injection remains the standard research route for soft-tissue indications.

How does BPC-157 compare to TB-500?

Both are investigational repair peptides but target different pathways. BPC-157 appears to accelerate angiogenesis and tendon/ligament remodeling. TB-500 (thymosin beta-4 fragment) promotes actin regulation and cell migration. Many protocols stack both — see our comparison.